Hi Stevie,
what price range are you anticipating for re-rate?
No doubt we'll break past previous ATH.
Tightly held, addressable market is huge, credible team and board, financially secured for P1 with pre-clinical results pointing to safe and favourable results
Held since IPO, day one it's had a unicorn feel to it. Their rate of progress and the potential effectiveness of ARG-007 itself relative our closest competitor is astounding, enough to make it to state news. '20 years in the making'
Cheers
Ann: Ethics Application Submitted for Phase 1 Trial, page-8
Add AGN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
77.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $95.24M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 650 | 79.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 82.5¢ | 20066 | 1 |
View Market Depth
| Last trade - 10.21am 31/07/2024 (20 minute delay) ? |
| AGN (ASX) Chart |
Day chart unavailable